Design Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Design Therapeutics, Inc. (DSGN) had Debt Securities, Available-for-sale, Amortized Cost of $195.26 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-03
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $195.26M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $210.32M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $202.59M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $190.52M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $195.26M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $210.32M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $202.59M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $190.52M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $196.27M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $215.56M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $222.44M 10-K · filed 2026-03-09 |
| 2024-09-30 | $222.83M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $215.53M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $241.46M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $260.54M 10-K · filed 2025-03-10 |
| 2023-09-30 | $264.28M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $277.89M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $288.56M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $307.24M 10-K · filed 2024-03-19 |
| 2022-09-30 | $305.58M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $242.04M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $85.23M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $85.74M 10-K · filed 2023-03-14 |
| 2021-09-30 | $36.06M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $32.01M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $10.64M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $33.56M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |